Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization

Alanna Morris, MD; Michael Weber, MD; Jeffrey J. Hsu, MD

March 13, 2023

SGLT2 inhibitors are recommended by the AHA/ACC/HFSA for patients with symptomatic chronic HFrEF, irrespective of the presence of type 2 diabetes. In two clinical trials, the addition of the SGLT2 inhibitors dapagliflozin and empagliflozin to standard therapies for patients with HFrEF resulted in a consistent ~25% relative risk reduction of the primary endpoint of cardiovascular death or hospitalization for heart failure.

SGLT2 inhibitors have also been shown to improve renal outcomes in patients with HFrEF. In trials of empagliflozin and dapagliflozin, no patients without diabetes developed ketoacidosis, although SGLT2 inhibitors do increase the risk for diabetic ketoacidosis in patients with diabetes and other high-risk conditions.

Learn more about the treatment of HFrEF.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Alanna Morris, Michael Weber, Jeffrey J. Hsu. Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization - Medscape - Mar 13, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Need a Curbside Consult? Share cases and questions with Physicians on Medscape Consult. Share a Case

Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Alanna Morris, MD

Michael Weber, MD

Jeffrey J. Hsu, MD

Comments

Email This

Feedback